Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged ≥18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses ≥2 months after the last recommended COVID-19 vaccine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
MMWR. Morbidity and mortality weekly report - 73(2024), 12 vom: 28. März, Seite 271-276 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.15585/mmwr.mm7312a5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370365739 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370365739 | ||
| 003 | DE-627 | ||
| 005 | 20240404235217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240330s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.15585/mmwr.mm7312a5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM370365739 | ||
| 035 | |a (NLM)38547037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Link-Gelles, Ruth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged ≥18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses ≥2 months after the last recommended COVID-19 vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Rowley, Elizabeth A K |e verfasserin |4 aut | |
| 700 | 1 | |a DeSilva, Malini B |e verfasserin |4 aut | |
| 700 | 1 | |a Dascomb, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, Stephanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Nicola P |e verfasserin |4 aut | |
| 700 | 1 | |a Grannis, Shaun J |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Toan C |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Zachary A |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming-Dutra, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a McEvoy, Charlene E |e verfasserin |4 aut | |
| 700 | 1 | |a Akinsete, Omobosola |e verfasserin |4 aut | |
| 700 | 1 | |a Bride, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Sheffield, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Naleway, Allison L |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbo, Ousseny |e verfasserin |4 aut | |
| 700 | 1 | |a Fireman, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, John |e verfasserin |4 aut | |
| 700 | 1 | |a Goddard, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Brian E |e verfasserin |4 aut | |
| 700 | 1 | |a Rogerson, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Fadel, William F |e verfasserin |4 aut | |
| 700 | 1 | |a Duszynski, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Suchitra |e verfasserin |4 aut | |
| 700 | 1 | |a Barron, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Reese, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Ball, Sarah W |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, Margaret M |e verfasserin |4 aut | |
| 700 | 1 | |a Natarajan, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Okwuazi, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Ami B |e verfasserin |4 aut | |
| 700 | 1 | |a Wiegand, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Tenforde, Mark W |e verfasserin |4 aut | |
| 700 | 1 | |a Payne, Amanda B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t MMWR. Morbidity and mortality weekly report |d 1984 |g 73(2024), 12 vom: 28. März, Seite 271-276 |w (DE-627)NLM012594334 |x 1545-861X |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2024 |g number:12 |g day:28 |g month:03 |g pages:271-276 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.15585/mmwr.mm7312a5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2024 |e 12 |b 28 |c 03 |h 271-276 | ||